Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2002 1
2005 1
2006 1
2010 2
2012 1
2013 1
2014 2
2016 1
2017 1
2018 1
2019 1
2021 1
2022 1
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis and management of neuroendocrine prostate cancer.
de Kouchkovsky I, Chan E, Schloss C, Poehlein C, Aggarwal R. de Kouchkovsky I, et al. Prostate. 2024 Apr;84(5):426-440. doi: 10.1002/pros.24664. Epub 2024 Jan 3. Prostate. 2024. PMID: 38173302 Review.
BACKGROUND: Although most patients with prostate cancer (PC) respond to initial androgen deprivation therapy (ADT), castration-resistant disease invariably develops. Progression to treatment-emergent neuroendocrine PC (t-NEPC) represents a unique mechanism of …
BACKGROUND: Although most patients with prostate cancer (PC) respond to initial androgen deprivation therapy (ADT), castration …
Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
Akamatsu S, Inoue T, Ogawa O, Gleave ME. Akamatsu S, et al. Int J Urol. 2018 Apr;25(4):345-351. doi: 10.1111/iju.13526. Epub 2018 Feb 3. Int J Urol. 2018. PMID: 29396873 Review.
Treatment-related neuroendocrine prostate cancer transdifferentiates from adenocarcinoma as an adaptive response to androgen receptor pathway inhibition. ...Typically, treatment-related neuroendocrine prostate cancer is characterized by either l …
Treatment-related neuroendocrine prostate cancer transdifferentiates from adenocarcinoma as an adaptive response to and …
Variants and unusual patterns of prostate cancer: clinicopathologic and differential diagnostic considerations.
Fine SW. Fine SW. Adv Anat Pathol. 2012 Jul;19(4):204-16. doi: 10.1097/PAP.0b013e31825c6b92. Adv Anat Pathol. 2012. PMID: 22692283 Review.
Beyond the typical acinar morphology observed in the majority of prostatic adenocarcinomas, a spectrum of morphologic variants and prostate cancer subtypes exists. These unusual entities may be classified as: (1) cancer morphologies arising by divergent di …
Beyond the typical acinar morphology observed in the majority of prostatic adenocarcinomas, a spectrum of morphologic variants …
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.
Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK; North American Neuroendocrine Tumor Society (NANETS). Strosberg JR, et al. Pancreas. 2010 Aug;39(6):799-800. doi: 10.1097/MPA.0b013e3181ebb56f. Pancreas. 2010. PMID: 20664477 Free PMC article.
Extrapulmonary poorly differentiated neuroendocrine carcinomas can originate in the gastrointestinal tract, bladder, cervix, and prostate. ...They are infrequently associated with secretory hormonal syndromes (such as the carcinoid syndrome) and rarely expres …
Extrapulmonary poorly differentiated neuroendocrine carcinomas can originate in the gastrointestinal tract, bladder, cervix, a …
Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective.
Monn MF, Cheng L. Monn MF, et al. Expert Rev Anticancer Ther. 2016 Oct;16(10):1029-37. doi: 10.1080/14737140.2016.1226137. Epub 2016 Aug 26. Expert Rev Anticancer Ther. 2016. PMID: 27534689 Review.
INTRODUCTION: Prostatic small cell carcinoma (PSCC) is a rare, aggressive form of prostate cancer associated with poor clinical outcomes. It can arise de novo or in the setting of castrate resistant adenocarcinoma of the prostate. Current the …
INTRODUCTION: Prostatic small cell carcinoma (PSCC) is a rare, aggressive form of prostate cancer associated with poor …
PEG10 is associated with treatment-induced neuroendocrine prostate cancer.
Kim S, Thaper D, Bidnur S, Toren P, Akamatsu S, Bishop JL, Colins C, Vahid S, Zoubeidi A. Kim S, et al. J Mol Endocrinol. 2019 Jul 1;63(1):39-49. doi: 10.1530/JME-18-0226. J Mol Endocrinol. 2019. PMID: 31013476
Neuroendocrine (NE) differentiation of advanced prostate adenocarcinoma following androgen receptor (AR) axis-directed therapy is becoming increasingly recognized. ...Using our unique model of enzalutamide resistance (ENZR) and NE differentia …
Neuroendocrine (NE) differentiation of advanced prostate adenocarcinoma following androgen receptor (AR) axis-di …
Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumors of the Prostate Gland: A Survey among Thirty-Nine Genitourinary Pathologists.
Mohanty SK, Lobo A, Williamson SR, Shah RB, Trpkov K, Varma M, Sirohi D, Aron M, Kandukari SR, Balzer BL, Luthringer DL, Ro J, Osunkoya AO, Desai S, Menon S, Nigam LK, Sardana R, Roy P, Kaushal S, Midha D, Swain M, Ambekar A, Mitra S, Rao V, Soni S, Jain K, Diwaker P, Pattnaik N, Sharma S, Chakrabarti I, Sable M, Jain E, Jain D, Samra S, Vankalakunti M, Mohanty S, Parwani AV, Sancheti S, Kumari N, Jha S, Dixit M, Malik V, Arora S, Munjal G, Gopalan A, Magi-Galluzzi C, Dhillon J. Mohanty SK, et al. Int J Surg Pathol. 2023 Sep;31(6):993-1005. doi: 10.1177/10668969221116629. Epub 2022 Aug 9. Int J Surg Pathol. 2023. PMID: 35946087
Background. Neuroendocrine differentiation in the prostate gland ranges from clinically insignificant neuroendocrine differentiation detected with markers in an otherwise conventional prostatic adenocarcinoma to a lethal high-grade …
Background. Neuroendocrine differentiation in the prostate gland ranges from clinically insignificant neuroendocrine …
New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
Sciarra A, Cardi A, Dattilo C, Mariotti G, Di Monaco F, Di Silverio F. Sciarra A, et al. Int J Clin Pract. 2006 Apr;60(4):462-70. doi: 10.1111/j.1742-1241.2006.00750.x. Int J Clin Pract. 2006. PMID: 16620361 Review.
In this review, we will present some of the information that is known about neuroendocrine (NE) cells and differentiation in the prostate. We will then speculate on the potential role that NE differentiation in prostate carcinoma may play and ho …
In this review, we will present some of the information that is known about neuroendocrine (NE) cells and differentiation in t …
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
Kim DH, Sun D, Storck WK, Welker Leng K, Jenkins C, Coleman DJ, Sampson D, Guan X, Kumaraswamy A, Rodansky ES, Urrutia JA, Schwartzman JA, Zhang C, Beltran H, Labrecque MP, Morrissey C, Lucas JM, Coleman IM, Nelson PS, Corey E, Handelman SK, Sexton JZ, Aggarwal R, Abida W, Feng FY, Small EJ, Spratt DE, Bankhead A 3rd, Rao A, Gesner EM, Attwell S, Lakhotia S, Campeau E, Yates JA, Xia Z, Alumkal JJ. Kim DH, et al. Clin Cancer Res. 2021 Sep 1;27(17):4923-4936. doi: 10.1158/1078-0432.CCR-20-4968. Epub 2021 Jun 18. Clin Cancer Res. 2021. PMID: 34145028 Free PMC article.
Lineage plasticity is a spectrum, but neuroendocrine prostate cancer (NEPC) is the most virulent example. Currently, there are limited treatments for NEPC. ...Furthermore, targetable factors that promote t-NEPC lineage plasticity are also unclear. EXPERIMENTAL DESIG …
Lineage plasticity is a spectrum, but neuroendocrine prostate cancer (NEPC) is the most virulent example. Currently, there are …
An orthotopic prostate cancer model for new treatment development using syngeneic or patient-derived tumors.
Chaudary N, Wiljer E, Foltz W, Thapa P, Hill RP, Milosevic M. Chaudary N, et al. Prostate. 2024 Jun;84(9):823-831. doi: 10.1002/pros.24701. Epub 2024 Apr 12. Prostate. 2024. PMID: 38606933
METHODS: This study describes a novel micro-surgical technique for orthotopically implanting intact tumors pieces from cell line derived (transgenic adenocarcinoma mouse prostate [TRAMP]-C2) or patient derived (neuroendocrine prostate cancer [NE …
METHODS: This study describes a novel micro-surgical technique for orthotopically implanting intact tumors pieces from cell line deri …
17 results